Involvement of the Epstein-Barr virus in the nasopharyngeal carcinoma pathogenesis

Medical Oncology

Volumn 22, Issue 2, 2005, Pages 113-121

  Burgos, Javier S ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Bcl 2; CD21; EBER; Epstein Barr virus; LMP1; Nasopharyngeal carcinoma; p53

Indexed keywords

COMPLEMENT COMPONENT C3D RECEPTOR; LATENT MEMBRANE PROTEIN 1; PROTEIN BCL 2; PROTEIN P53;

CARCINOGENESIS; EPSTEIN BARR VIRUS; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; NASOPHARYNX CARCINOMA; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; TUMOR CELL; UPREGULATION;

EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; NASOPHARYNGEAL NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53; VIRAL PROTEINS;

EID: 22344443201     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:22:2:113     Document Type: Review

References (57)

1. Liebowitz D. Nasopharyngeal carcinoma: the Epstein-Barr virus association. Semin Oncol 1994; 21:376-381.
2. Borza CM, Hutt-Fletcher LM. Alternate replication in B cells and epithelial cells switches tropism of Epstein-Barr virus. Nat Med 2002; 8:594-599.
3. Niedobitek G, Young LS. Epstein-Barr virus persistence and virus-associated tumours. Lancet 1994; 343:333-335.
4. Pathmanathan R, Prasad U, Sadler R, Flynn K, Raab-Traub N. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N Engl J Med 1995; 333:693-698.
5. Epstein MA, Barr YM, Achong BG. Preliminary observations on new lymphoblast strains (EB4, EB5) from Burkitt tumours in a British and a Ugandan patient. Br J Cancer 1966; 20:475-479.
6. Shanmugaratnam K, Sobin LH. The World Health Organization histological classification of tumours of the upper respiratory tract and ear. A commentary on the second edition. Cancer 1993; 71:2689-2697.
7. Fingeroth JD, Diamond ME, Sage DR, Hayman J, Yates JL. CD21-dependent infection of an epithelial cell line, 293, by Epstein-Barr virus. J Virol 1999; 73:2115-2125.
8. Imai S, Nishikawa J, Takada K. Cell-to-cell contact as an efficient mode of Epstein-Barr virus infection of diverse human epithelial cells. J Virol 1998; 72:4371-4378.
9. Vera-Sempere F, Burgos J, Botella MS, Morera C. Comparative analysis of Epstein-Barr virus (EBV) detection by nested-PCR and non-isotopic in situ hybridization in nasopharyngeal carcinoma (NPC). Clin Chim Acta 1998; 271:119-132.
10. Vera-Sempere FJ, Burgos JS, Botella MS, Cordoba J, Gobernado M. Immunohistochemical expression of Epstein-Barr virus-encoded latent membrane protein (LMP-1) in paraffin sections of EBV-associated nasopharyngeal carcinoma in Spanish patients. Eur J Cancer B Oral Oncol 1996; 32B:163-168.
11. Burgos JS, Vera-Sempere FJ. Analysis of EBV latency by EBER in situ hybridization in nasopharyngeal carcinoma Spanish patients. Anticancer Res 2001; 21:3921-3924.
12. Fingeroth JD, Weis JJ, Tedder TF, Strominger JL, Biro PA, Fearon DT. Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc Natl Acad Sci USA 1984; 81:4510-4514.
13. Young LS, Clark D, Sixbey JW, Rickinson AB. Epstein-Barr virus receptors on human pharyngeal epithelia. Lancet 1986; 1:240-242.
14. Birkenbach M, Tong X, Bradbury LE, Tedder TF, Kieff E. Characterization of an Epstein-Barr virus receptor on human epithelial cells. J Exp Med 1992; 176:1405-1414.
15. Burgos JS, Vera-Sempere FJ. Immunohistochemical absence of CD21 membrane receptor in nasopharyngeal carcinoma cells infected by Epstein-Barr virus in Spanish patients. Laryngoscope 2000; 110:2081-2084.
16. Billaud M, et al. Epstein-Barr virus (EBV)-containing nasopharyngeal carcinoma cells express the B-cell activation antigen blast2/CD23 and low levels of the EBV receptor CR2. J Virol 1989; 63:4121-4128.
17. Busson P, et al. Establishment and characterization of three transplantable EBV-containing nasopharyngeal carcinomas. Int J Cancer 1988; 42:599-606.
18. Glickman JN, Howe JG, Steitz JA. Structural analyses of EBER1 and EBER2 ribonucleoprotein particles present in Epstein-Barr virus-infected cells. J Virol 1988; 62:902-911.
19. Wu TC, et al. Abundant expression of EBER1 small nuclear RNA in nasopharyngeal carcinoma. A morphologically distinctive target for detection of Epstein-Barr virus in formalin-fixed paraffin-embedded carcinoma specimens. Am J Pathol 1991: 138:1461-1469.
20. Lerner MR, Andrews NC, Miller G, Steitz JA. Two small RNAs encoded by Epstein-Barr virus and complexed with protein are precipitated by antibodies from patients with systemic lupus erythematosus. Proc Natl Acad Sci USA 1981; 78:805-809.
21. Hudson GS, Farrell PJ, Barrell BG. Two related but differentially expressed potential membrane proteins encoded by the EcoRI Dhet region of Epstein-Barr virus B95-8. J Virol 1985; 53:528-535.
22. Wang D, Liebowitz D, Kieff E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 1985; 43:831-840.
23. Moorthy RK, Thorley-Lawson DA. All three domains of the Epstein-Barr virus-encoded latent membrane protein LMP-1 are required for transformation of rat-1 fibroblasts. J Virol 1993; 67:1638-1646.
24. Martin JM, Veis D, Korsmeyer SJ, Sugden B. Latent membrane protein of Epstein-Barr virus induces cellular phenotypes independently of expression of Bcl-2. J Virol 1993; 67:5269-5278.
25. Uchida J, et al. Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses. Science 1999; 286:300-303.
26. Hatzivassiliou E, Mosialos G. Cellular signaling pathways engaged by the Epstein-Barr virus transforming protein LMP1. Front Biosci 2002; 7:d319-329.
27. Henderson S, et al. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 1991; 65:1107-1115.
28. Tsujimoto Y, Gorham J, Cossman J, Jaffe E, Croce CM. The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science 1985; 229:1390-1393.
29. Cleary ML, Smith SD, Sklar J. Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell 1986; 47:19-28.
30. Dawson CW, Eliopoulos AG, Dawson J, Young LS. BHRF1, a viral homologue of the Bcl-2 oncogene, disturbs epithelial cell differentiation. Oncogene 1995; 10:69-77.
31. Korsmeyer SJ. Bcl-2: an antidote to programmed cell death. Cancer Surv 1992; 15:105-118.
32. Vera-Sempere FJ, Burgos JS, Botella MS, Morera C. Immunohistochemical expression of Bcl-2 oncoprotein in EBV-associated nasopharyngeal carcinoma correlated to histological type and survival. Histol Histopathol 1997; 12:9-18.
33. Kouvidou Ch KP, et al. Expression of Bcl-2 and p53 proteins in nasopharyngeal carcinoma. Absence of correlation with the presence of EBV encoded EBER1-2 transcripts and latent membrane protein-1. J Clin Pathol Mol Pathol 1995; 148:M17-22.
34. Lu QL, Elia G, Lucas S, Thomas JA. Bcl-2 proto-oncogene expression in Epstein-Barr-virus-associated nasopharyngeal carcinoma. Int J Cancer 1993; 53:29-35.
35. Lane DP. p53 and human cancers. Br Med Bull 1994; 50:582-599.
36. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253:49-53.
37. Chang F SS, Kurvinen K, Syrjanen K. The p53 tumor suppressor gene as a common cellular target in human carcinogenesis. Am J Gastroenterol 1993; 88:174-186.
38. Niedobitek G, Agathanggelou A, Barber P, Smallman LA, Jones EL, Young LS. P53 overexpression and Epstein-Barr virus infection in undifferentiated and squamous cell nasopharyngeal carcinomas. J Pathol 1993; 170:457-461.
39. Maestro R, et al. High frequency of p53 gene alterations associated with protein overexpression in human squamous cell carcinoma of the larynx. Oncogene 1992; 7:1159-1166.
40. Sakai E, Tsuchida N. Most human squamous cell carcinomas in the oral cavity contain mutated p53 tumor-suppressor genes. Oncogene 1992; 7:927-933.
41. Niemhom S, Kitazawa S, Murao S, Kunachak S, Maeda S. Co-expression of p53 and bcl-2 may correlate to the presence of epstein-barr virus genome and the expression of proliferating cell nuclear antigen in nasopharyngeal carcinoma. Cancer Lett 2000; 160:199-208.
42. Spruck CH, 3rd, et al. Absence of p53 gene mutations in primary nasopharyngeal carcinomas. Cancer Res 1992; 52:4787-4790.
43. Sun Y, et al. An infrequent point mutation of the p53 gene in human nasopharyngeal carcinoma. Proc Natl Acad Sci USA 1992; 89:6516-6520.
44. Nasrin N, Taiba K, Hannan N, Hannan M, al-Sedairy S. A molecular study of EBV DNA and p53 mutations in nasopharyngeal carcinoma of Saudi Arab patients. Cancer Lett 1994; 82:189-198.
45. Kouvidou C, et al. P21/waf1 protein expression in nasopharyngeal carcinoma. Comparative study with PCNA, p53 and MDM-2 protein expression. Anticancer Res 1997; 17:2615-2619.
46. Burgos JS. Absence of p53 alterations in nasopharyngeal carcinoma Spanish patients with Epstein-Barr virus infection. Virus Genes 2003; 27:263-268.
47. Rubio L, Burgos JS, Lopez-Guerrero JA, Morera C, Vera-Sempere FJ. Expression of p53 protein and tumor angiogenesis as prognostic factors in nasopharyngeal carcinoma patients. Pathol Res Pract 2002; 198:97-102.
48. Bhargava V, et al. The association of p53 immunopositivity with tumor proliferation and other prognostic indicators in breast cancer. Mod Pathol 1994; 7:361-368.
49. Hurlimann J, Chaubert P, Benhattar J. p53 Gene alterations and p53 protein accumulation in infiltrating ductal breast carcinomas: correlation between immunohistochemical and molecular biology techniques. Mod Pathol 1994; 7:423-428.
50. Thor AD, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992; 84:845-855.
51. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990; 248:76-79.
52. Lane DP, Crawford LV. T antigen is bound to a host protein in SV40-transformed cells. Nature 1979; 278:261-263.
53. Linzer DI, Levine AJ. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 1979; 17:43-52.
54. Old LJ BE, Oettgen HF, dé-Harven E, Geering G, Williamson B. Precipitating antibody in human serum to an antigen present in cultured Burkitt's lymphoma cells. Proc Natl Acad Sci USA 1966; 56:1699-1704.
55. Nonoyama M, Huang CH, Pagano JS, Klein G, Singh S. DNA of Epstein-Barr virus detected in tissue of Burkitt's lymphoma and nasopharyngeal carcinoma. Proc Natl Acad Sci USA 1973; 70:3265-3268.
56. Wolf H, zur Hausen H, Becker V. EB viral genomes in epithelial nasopharyngeal carcinoma cells. Nat New Biol 1973; 244:245-247.
57. Klein G, Giovanella BC, Lindahl T, Fialkow PJ, Singh S, Stehlin JS. Direct evidence for the presence of Epstein-Barr virus DNA and nuclear antigen in malignant epithelial cells from patients with poorly differentiated carcinoma of the nasopharynx. Proc Natl Acad Sci USA 1974; 71:4737-4741.